Norway, biosimilars in different funding systems. What works?

GaBI Journal

Volumn 4, Issue 2, 2015, Pages 90-92

  Mack, Asbjørn ^a  

^a Legemiddelinnkjøpssamarbeidet ^*  (Norway)

Author keywords

Biosimilars; Discounts; Market penetration; Tender

Indexed keywords

BIOSIMILAR AGENT; FILGRASTIM; GENERIC DRUG; HUMAN GROWTH HORMONE; INFLIXIMAB; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PEGFILGRASTIM; RECOMBINANT ERYTHROPOIETIN;

ARTICLE; BUDGET; COST CONTROL; DRUG APPROVAL; DRUG COST; DRUG MARKETING; DRUG UTILIZATION; ECONOMIC ASPECT; FUNDING; HUMAN; NATIONAL HEALTH INSURANCE; NORWAY;

EID: 85008258391     PISSN: 20336403     EISSN: 20336772     Source Type: Journal    
DOI: 10.5639/gabij.2015.0402.018     Document Type: Article

References (2)

1. Statens legemiddelverk Norwegian Medicines Agency. Tenk pris ved forskrivning av veksthormon [homepage on the Internet]. [cited 2015 May 22]. Available from: http://www.legemiddelverket.no/Nyheter/Blaa_resept_og_pris/Sider/Tenk-pris-ved-forskrivning-av-veksthormon.aspx
2. GaBI Online -Generics and Biosimilars Initiative. Norwegian study may be slowing adoption of biosimilar infliximab fails [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2015 May 22]. Available from: www:gabionline.net/Biosimilars/News/Norwegian-study-may-be-slowing-adoption-of-biosimilar-infliximab